Evidence map›Paper›PMID 40186715›Full record

ArticleMycopathologia2025

Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center.

Hedda Luise Verhasselt, Lara Thissen, Ulrike Scharmann, Silke Dittmer, Peter-Michael Rath, Joerg Steinmann, Lisa Kirchhoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026
    Article
  2. Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026
    Review
  3. Review
  4. A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026
    Article
  5. Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hedda Luise VerhasseltInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany. hedda-luise.verhasselt@uk-essen.de.ORCID http://orcid.org/0000-0002-5601-2444
Lara ThissenInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Ulrike ScharmannInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Silke DittmerInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Peter-Michael RathInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Joerg SteinmannInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Lisa KirchhoffInstitute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numbers of infections with azole-resistant Aspergillus fumigatus (ARAf) were rising in the last decades. We assessed ARAf susceptibility trends towards five antifungal agents (amphotericin B (AMB), itraconazole (ITR), voriconazole (VCZ), olorofim (OLO) and manogepix (MGX)) over twelve years in a German Excellence Center for Medical Mycology (ECMM). In addition, underlying mutations were studied and correlated with trends in minimum inhibitory concentration (MIC). Broth microdilution (BMD) was performed following EUCAST guidelines for 143 clinical ARAf isolates collected between the years 2011 and 2022 in a West German tertiary care centre. BMD was carried out for all antifungal agents in the following concentration ranges: 0.016-8 mg/L for AMB, ITR and VCZ as well as 0.001-0.5 mg/L for OLO and 0.004-2 mg/L for MGX. Molecular assays on mutations associated with antifungal resistance were performed for all 143 isolates (AsperGenius® 1.0, Pathonostics, Maastricht, The Netherlands) and for a total of ten non TR

Indexed as

Antifungal AgentsAspergillosisAspergillus fumigatusAzolesDrug Resistance, FungalFungal ProteinsGermanyHumansMicrobial Sensitivity TestsMutationTertiary Care CentersAntifungal AgentsAzolesFungal ProteinsAspergillusAzole-resistanceCYP51AManogepixOlorofim

Identifiers

PMID40186715
PMCPMC11972221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.